Balance Sheet
Accumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GP-Act III Acquisition (GPAT) Cash & Equivalents (2023 - 2025)

GP-Act III Acquisition (GPAT) has disclosed Cash & Equivalents for 3 consecutive years, with $112660.0 as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 76.7% to $112660.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $112660.0 through Dec 2025, down 76.7% year-over-year, with the annual reading at $112660.0 for FY2025, 76.7% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $112660.0 at GP-Act III Acquisition, down from $145453.0 in the prior quarter.
  • The five-year high for Cash & Equivalents was $571765.0 in Q2 2024, with the low at $1208.0 in Q4 2023.
  • Average Cash & Equivalents over 3 years is $260557.3, with a median of $199755.5 recorded in 2024.
  • The sharpest move saw Cash & Equivalents soared 39930.79% in 2024, then crashed 76.7% in 2025.
  • GP-Act III Acquisition's Cash & Equivalents stood at $1208.0 in 2023, then soared by 39930.79% to $483572.0 in 2024, then crashed by 76.7% to $112660.0 in 2025.
  • Per Business Quant, the three most recent readings for GPAT's Cash & Equivalents are $112660.0 (Q4 2025), $145453.0 (Q3 2025), and $246314.0 (Q2 2025).